222 related articles for article (PubMed ID: 30275698)
1. Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
Fernet M; Beckerman B; Abreu P; Lins K; Vincent J; Burgess E
Vasc Health Risk Manag; 2018; 14():233-246. PubMed ID: 30275698
[TBL] [Abstract][Full Text] [Related]
2. Eplerenone for hypertension.
Tam TS; Wu MH; Masson SC; Tsang MP; Stabler SN; Kinkade A; Tung A; Tejani AM
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD008996. PubMed ID: 28245343
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
4. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.
Weinberger MH; Roniker B; Krause SL; Weiss RJ
Am J Hypertens; 2002 Aug; 15(8):709-16. PubMed ID: 12160194
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
[TBL] [Abstract][Full Text] [Related]
7. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
[TBL] [Abstract][Full Text] [Related]
9. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis.
Pelliccia F; Patti G; Rosano G; Greco C; Gaudio C
Int J Cardiol; 2014 Nov; 177(1):219-28. PubMed ID: 25499383
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of aldosterone blockade.
Weber MA
Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
[TBL] [Abstract][Full Text] [Related]
12. Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension.
Schneider A; Schwab J; Karg MV; Kalizki T; Reinold A; Schneider MP; Schmieder RE; Schmidt BM
J Hypertens; 2017 May; 35(5):1086-1092. PubMed ID: 28118280
[TBL] [Abstract][Full Text] [Related]
13. Eplerenone: a review of its use in essential hypertension.
Croom KF; Perry CM
Am J Cardiovasc Drugs; 2005; 5(1):51-69. PubMed ID: 15631538
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
Burgess ED; Lacourcière Y; Ruilope-Urioste LM; Oparil S; Kleiman JH; Krause S; Roniker B; Maurath C
Clin Ther; 2003 Sep; 25(9):2388-404. PubMed ID: 14604739
[TBL] [Abstract][Full Text] [Related]
15. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
16. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
[TBL] [Abstract][Full Text] [Related]
17. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
[TBL] [Abstract][Full Text] [Related]
18. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.
Walsh M; Manns B; Garg AX; Bueti J; Rabbat C; Smyth A; Tyrwhitt J; Bosch J; Gao P; Devereaux PJ; Wald R
Clin J Am Soc Nephrol; 2015 Sep; 10(9):1602-8. PubMed ID: 26138259
[TBL] [Abstract][Full Text] [Related]
19. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Krum H; Nolly H; Workman D; He W; Roniker B; Krause S; Fakouhi K
Hypertension; 2002 Aug; 40(2):117-23. PubMed ID: 12154100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]